Last updated: March 19, 2026
What is the drug associated with NDC 24979-0029?
NDC 24979-0029 corresponds to Venclexta (venetoclax), manufactured by AbbVie. It is approved for treating chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain acute myeloid leukemia (AML) cases in combination with other agents.
Market Overview
Market Size and Demand Drivers
Regulatory and Market Expansion
- Approval extensions include first-line treatment indications for CLL and combination with obinutuzumab.
- Ongoing trials target additional hematological malignancies, expanding potential market size.
Price Projection Factors
Current Pricing
- Wholesale Acquisition Cost (WAC): ~$13,750 per month.
- Average Sales Price (ASP): Slightly lower, reflecting discounts and rebates.
- Net Price Estimates: Often 50-70% of WAC due to rebates.
Projected Trends
| Factor |
Impact on Price |
| Increased Competition |
May drive price reductions as biosimilars or generics enter. |
| Expanded Indication Use |
Could sustain or slightly increase pricing due to higher demand. |
| Rebate and Negotiation Trends |
Potential price discounts amid payor push for access. |
| Manufacturing Costs |
Slight reduction with process optimization; minimal impact on list price. |
Forecast Over Next 3-5 Years
- Price Stability: Expect list prices to remain largely stable or decline marginally (2-4%) annually, driven by negotiations, market share shifts, and biosimilar competition.
- Net Prices: Likely to decrease more substantially, influenced by payor discounts and rebates.
Potential for Price Increase
- Limited, as the drug is already high-cost and acceptance by payors has plateaued.
- New indications or formulations may command premium pricing but are unlikely to significantly alter existing price levels.
Market Revenue Projections
| Year |
Estimated Market Volume (patients) |
Estimated Revenue (USD millions) |
Assumptions |
| 2023 |
20,000 |
330 |
400 mg daily, average net price of $12,000/month |
| 2024 |
22,000 |
396 |
10% volume increase, slight price decline |
| 2025 |
24,000 |
440 |
Continued growth, stable pricing |
Note: These projections exclude potential shifts from biosimilars or generic competitors.
Key Market Risks
- Entry of biosimilars could lower prices.
- Regulatory restrictions or new safety data might impact demand.
- Reimbursement policies vary across countries, affecting global pricing.
Summary
- The global market for venetoclax is growing due to expanded indications.
- List prices are stable but net prices are declining due to negotiations.
- Market volume increases at approximately 10% annually.
- Price projections suggest marginal declines in list prices, with potential for stabilization or slight increases in net revenues depending on reimbursement dynamics.
Key Takeaways
- NDC 24979-0029 (Venclexta) has a stable high list price, with significant usage in hematological cancers.
- Market growth driven by indication expansion and increased adoption.
- Price pressures are likely from biosimilar entry and payor negotiations.
- Revenue growth depends on volume increases and reimbursement trends.
- The future price trajectory will hinge on competitive dynamics and regulatory changes.
FAQs
1. Will the price of venetoclax decrease significantly in the next five years?
It is unlikely. While net prices may decline due to rebates, list prices are expected to remain relatively stable owing to high market demand and limited direct competition at the brand level.
2. How do biosimilars influence venetoclax pricing?
Biosimilars for rituximab and other combination partner drugs may lower overall treatment costs but are less likely to directly reduce venetoclax’s list price. They could, however, influence reimbursement and purchasing strategies.
3. Which regions have the highest market potential for venetoclax?
The U.S. remains the largest market, followed by Europe and parts of Asia-Pacific. Emerging markets could see increased use as local approvals and healthcare infrastructure expand.
4. What indications are driving revenue growth for venetoclax?
Treatment of CLL, SLL, and AML in combination therapies contribute most to growth. Expansion into earlier lines of therapy and additional hematologic cancers may enhance demand.
5. What are the key factors that could alter market size and pricing?
New competing therapies, regulatory changes, safety profile updates, and price negotiations are primary factors affecting future market dynamics.
References
[1] U.S. Food and Drug Administration. (2019). Venclexta (venetoclax) prescribing information.
[2] IQVIA. (2022). Global Oncology Market Report.
[3] SSR Health. (2022). Brand Price Trends for Hematology Drugs.
[4] FDA. (2023). Expanded indications for venetoclax.
[5] Bloomberg Intelligence. (2023). Hematology drug market analysis.
